Real-world outcomes of ustekinumab, vedolizumab, and tumor necrosis factor inhibitors in very-early-onset inflammatory bowel disease: a multi-center cohort study
Journal of Gastroenterology · 2026-04 · 61 (4) · 398-409
DOI: 10.1007/s00535-025-02334-9 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Gastroenterology, online erschienen am 03.01.2026. Verfasst von Ryusuke Nambu und 23 weiteren Autor:innen. Beteiligte Einrichtung: Center for Pediatric Inflammatory Bowel Disease, Division of Gastroenterology and Hepatology, Saitama Children's Medical Center, 1-2 Shintoshin, Chuo…. Hauptthemen laut MEDLINE: Ustekinumab, Antibodies, Monoclonal, Humanized, Gastrointestinal Agents, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Very-early-onset inflammatory bowel disease (VEO-IBD), representing cases diagnosed before age 6 years, is increasing in prevalence. Although VEO-IBD often presents as severe, treatment-resistant disease requiring biologic agents, studies showing the effectiveness of biologics, such as ustekinumab (UST) and vedolizumab (VDZ), remain limited.
Methods
We retrospectively analyzed patients with VEO-IBD treated for at least a year from 13 institutions in Japan, evaluating clinical course including effectiveness of biologics, such as infliximab (IFX), adalimumab (ADL), UST, and VDZ. Patients with monogenic IBD were excluded. Steroid-free clinical remission (SFCR) and treatment persistence were assessed separately for first-line and for second-line or subsequent biologic therapies.
Results
We studied 101 VEO-IBD patients (56% male; median age, 3.6 years), including 40 with Crohn’s disease, 52 with ulcerative colitis, and 9 with unclassified IBD. Biologics were used in 67 patients, most commonly infliximab (IFX; n = 52), followed by UST ( n = 38), adalimumab (ADL; n = 23), and VDZ ( n = 21). As first-line therapy, IFX and ADL achieved 1-year SFCR rates of 19% and 46%, with persistence rates of 36% and 48%. Despite being used mainly as second-line or subsequent therapies, UST and VDZ showed 1-year SFCR rates of about 45% and 36%, and maintained persistence of 79% and 46%, respectively, with UST demonstrating higher persistence than TNF-α inhibitors ( P < 0.01). No discontinuations due to infusion reactions or other adverse events occurred with UST or VDZ.
Conclusion
UST and VDZ were effective and well tolerated even when used as second-line or subsequent therapies for VEO-IBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Pediatric Inflammatory Bowel Disease, Division of Gastroenterology and Hepatology, Saitama Children's Medical Center, 1-2 Shintoshin, Chuo-Ku, Saitama, 3308777, Japan. nambee1231@gmail.com.
- Center for Pediatric Inflammatory Bowel Disease, Division of Gastroenterology and Hepatology, Saitama Children's Medical Center, 1-2 Shintoshin, Chuo-Ku, Saitama, 3308777, Japan.
- Center for Pediatric Inflammatory Bowel Disease, Division of Gastroenterology, National Center for Child Health and Development, Tokyo, Japan.
- Department of Gastroenterology, Nutrition and Endocrinology, Osaka Women's and Children's Hospital, Osaka, Japan.
- Department of Pediatrics, Osaka Medical and Pharmaceutical University, Osaka, Japan.
- Department of Pediatrics, Kawanishi City Medical Center, Hyogo, Japan.
ORCID-Profile: Ryusuke Nambu
Zitieren
APA
Nambu, R., Iwama, I., Takeuchi, I., Hagiwara, S. I., Etani, Y., Kaji, E., Yoden, A., Kakuta, F., Hoshi, Y., Tsumura, N., Mizuochi, T., Kumagai, H., Yokoyama, K., Nishizawa, T., Usami, M., Takaki, Y., Ebana, R., Kurasawa, S., Fujikawa, H., …, & Arai, K. (2026). Real-world outcomes of ustekinumab, vedolizumab, and tumor necrosis factor inhibitors in very-early-onset inflammatory bowel disease: a multi-center cohort study. Journal of Gastroenterology, 61(4), 398-409. https://doi.org/10.1007/s00535-025-02334-9
Vancouver
Nambu R, Iwama I, Takeuchi I, Hagiwara SI, Etani Y, Kaji E, et al. Real-world outcomes of ustekinumab, vedolizumab, and tumor necrosis factor inhibitors in very-early-onset inflammatory bowel disease: a multi-center cohort study. Journal of Gastroenterology. 2026;61(4):398-409. doi:10.1007/s00535-025-02334-9
BibTeX
@article{Nambu2026,
author = {Nambu, Ryusuke and Iwama, Itaru and Takeuchi, Ichiro and Hagiwara, Shin-Ichiro and Etani, Yuri and Kaji, Emiri and Yoden, Atsushi and Kakuta, Fumihiko and Hoshi, Yusuke and Tsumura, Naoya and Mizuochi, Tatsuki and Kumagai, Hideki and Yokoyama, Koji and Nishizawa, Takuya and Usami, Masaaki and Takaki, Yugo and Ebana, Ryo and Kurasawa, Shingo and Fujikawa, Hiroki and Ishige, Takashi and Kudo, Takahiro and Yoshida, M Masashi and Shimizu, Hirotaka and Arai, Katsuhiro},
title = {Real-world outcomes of ustekinumab, vedolizumab, and tumor necrosis factor inhibitors in very-early-onset inflammatory bowel disease: a multi-center cohort study},
journal = {Journal of Gastroenterology},
year = {2026},
volume = {61},
number = {4},
pages = {398--409},
doi = {10.1007/s00535-025-02334-9}
}
EUVIMED